Literature DB >> 21695425

Late effects of childhood leukemia therapy.

Joy M Fulbright1, Sripriya Raman, Wendy S McClellan, Keith J August.   

Abstract

As survival rates for children treated for childhood cancers become significantly better, the focus is increasingly on determining the late effects of treatments and the best ways to monitor for them and prevent their occurrence. This review focuses on recent literature discussing the late effects of treatment in patients treated for acute myeloid leukemia and acute lymphoblastic leukemia during childhood. The late effects of therapy for childhood leukemia include secondary malignancy, cardiotoxicity, obesity, endocrine abnormalities, reproductive changes, neurocognitive deficits, and psychosocial effects. As clinicians have become more aware of the late effects of therapy, treatment regimens have been changed to decrease late effects, but patients still require long-term follow-up for their prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695425     DOI: 10.1007/s11899-011-0094-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  132 in total

Review 1.  Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study.

Authors:  Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

2.  Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia.

Authors:  E Raymond-Speden; G Tripp; B Lawrence; D Holdaway
Journal:  J Pediatr Psychol       Date:  2000-03

3.  Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity.

Authors:  Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman
Journal:  Pediatr Blood Cancer       Date:  2005-09       Impact factor: 3.167

4.  Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.

Authors:  Brenda J Spiegler; Kimberly Kennedy; Ronnen Maze; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler; Paul C Nathan
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

Authors:  K Sorensen; G Levitt; C Bull; J Chessells; I Sullivan
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 6.  Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors.

Authors:  Patricia K Duffner
Journal:  Neurologist       Date:  2004-11       Impact factor: 1.398

7.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Nader Rifai; Virginia M Dalton; Donna E Levy; Lewis B Silverman; Stuart R Lipsitz; Steven D Colan; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Richard D Gelber; Stephen E Sallan
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

Authors:  Vladan Rajić; Richard Aplenc; Marusa Debeljak; Veronika Velensek Prestor; Natasa Karas-Kuzelicki; Irena Mlinaric-Rascan; Janez Jazbec
Journal:  Leuk Lymphoma       Date:  2009-10

Review 9.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia.

Authors:  Ching-Hon Pui; Scott C Howard
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

10.  Employment status among adult survivors in the Childhood Cancer Survivor Study.

Authors:  Jenny W Y Pang; Debra L Friedman; John A Whitton; Marilyn Stovall; Ann C Mertens; Leslie L Robison; Noel S Weiss
Journal:  Pediatr Blood Cancer       Date:  2008-01       Impact factor: 3.838

View more
  11 in total

1.  Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study.

Authors:  Lindsey Christoffersen; Todd M Gibson; Ching-Hon Pui; Vijaya Joshi; Robyn E Partin; Daniel M Green; Jennifer Q Lanctot; Carrie R Howell; Daniel A Mulrooney; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  Pediatr Blood Cancer       Date:  2020-05-08       Impact factor: 3.167

2.  Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries.

Authors:  Gitte Vrelits Sørensen; Jeanette Falck Winther; Sofie de Fine Licht; Klaus Kaa Andersen; Anna Sällfors Holmqvist; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Andrea Bautz; Timothy L Lash; Henrik Hasle
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

3.  Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross sectional study.

Authors:  Zsila S Sadighi; Kirsten K Ness; Melissa M Hudson; E Brannon Morris; Davonna S Ledet; Ching-Hon Pui; Scott C Howard; Kevin R Krull; Emily Browne; Debbie Crom; Pamela S Hinds; Liang Zhu; Deokumar Srivastava; Raja B Khan
Journal:  Eur J Paediatr Neurol       Date:  2014-07-05       Impact factor: 3.140

Review 4.  Health promotion for adolescent childhood leukemia survivors: building on prevention science and ehealth.

Authors:  Diane L Elliot; Susan J Lindemulder; Linn Goldberg; Diane D Stadler; Jennifer Smith
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

5.  Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers.

Authors:  Nadja Chevalier; Nicole Gross; Christian Widmann
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

6.  Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.

Authors:  Matthew R Hart; Donovan J Anderson; Christopher C Porter; Tobias Neff; Michael Levin; Marshall S Horwitz
Journal:  PLoS Genet       Date:  2018-09-14       Impact factor: 5.917

7.  Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.

Authors:  Judit C Sági; Bálint Egyed; Andrea Kelemen; Nóra Kutszegi; Márta Hegyi; András Gézsi; Martina Ayaka Herlitschke; Andrea Rzepiel; Lili E Fodor; Gábor Ottóffy; Gábor T Kovács; Dániel J Erdélyi; Csaba Szalai; Ágnes F Semsei
Journal:  BMC Cancer       Date:  2018-07-03       Impact factor: 4.430

8.  Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Judit C Sági; András Gézsi; Bálint Egyed; Zsuzsanna Jakab; Noémi Benedek; Andishe Attarbaschi; Stefan Köhrer; Jakub Sipek; Lucie Winkowska; Marketa Zaliova; Stavroula Anastasopoulou; Benjamin Ole Wolthers; Susanna Ranta; Csaba Szalai; Gábor T Kovács; Ágnes F Semsei; Dániel J Erdélyi
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  CD47-ligation induced cell death in T-acute lymphoblastic leukemia.

Authors:  Pascal Leclair; Chi-Chao Liu; Mahdis Monajemi; Gregor S Reid; Laura M Sly; Chinten James Lim
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

10.  Toward prevention of childhood ALL by early-life immune training.

Authors:  Julia Hauer; Ute Fischer; Arndt Borkhardt
Journal:  Blood       Date:  2021-10-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.